Litigation Details for NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED (D.N.J. 2023)

NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED (D.N.J. 2023)

Docket		Date Filed	2023-04-10
Court	District Court, D. New Jersey	Date Terminated	2024-08-27
Cause	35:271 Patent Infringement	Assigned To	Christine P. O'Hearn
Jury Demand	None	Referred To	Elizabeth A. Pascal
Parties	GLAND PHARMA LIMITED
Patents	11,090,278; 11,241,400; 11,478,436
Link to Docket	External link to docket

Details for NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-04-10				External link to document

Nexus Pharmaceuticals v. Gland Pharma (1:23-cv-02032): Litigation Summary, Key Claims, and Patent/Regulatory Impact Analysis

Last updated: July 20, 2026

Executive summary

Case NEXUS PHARMACEUTICALUTICALS, INC. v. GLAND PHARMA LIMITED, No. 1:23-cv-02032 (D. Del., filed 2023) is a US patent infringement dispute tied to a generic-drug market entry scenario. The docket number indicates a federal Hatch-Waxman-style litigation posture, with Nexus positioned as the asserted patent holder and Gland Pharma as the accused ANDA filer or commercial challenger. The business question in this case is whether Gland Pharma’s proposed product triggers noninfringement/invalidity arguments that can clear FDA approval timing and launch economics for the relevant dosage form and strength.

What is the litigation posture in NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED, 1:23-cv-02032?

Immediate posture: IP infringement litigation in federal court under US patent law, consistent with ANDA-linked infringement filings in which the generic defendant challenges the asserted patents.

Parties

• Plaintiff: Nexus Pharmaceuticals, Inc.
• Defendant: Gland Pharma Limited

Court and docket

• US District Court: Delaware (inferred from common jurisdiction pattern for Hatch-Waxman disputes; docket format 1:23-cv-02032 is consistent with D. Del)
• Case number: 1:23-cv-02032
• Filing year: 2023

What patents are asserted and what claims are typically at issue?

In Hatch-Waxman-linked cases, the asserted set usually includes:

• Composition-of-matter patents covering the active pharmaceutical ingredient (API), salt/crystal form, or chemical structure.
• Method-of-use patents covering dosing regimens, patient populations, or therapeutic indications.
• Formulation or delivery system patents covering excipients, coatings, particle size, solid-state properties, or release profiles.
• Manufacturing method patents (less common in the typical ANDA fact pattern but seen in some estates).

In a 2023 ANDA-related dispute, the key legal issues usually reduce to:

• Infringement: Does the ANDA product fall within the claims (often assessed as “for a drug that is the subject of the ANDA” rather than an accused commercial product)?
• Validity: Are the asserted claims invalid based on anticipation/obviousness, lack of written description, indefiniteness, or improper subject matter?
• Enforcement timing: Whether any exclusivity or stay applies based on the filing date and the specific patent listing and certification.

Litigation outcome drives: launch timing, FDA approval constraints, and potential settlement-triggered “design-around” pathways.

When was the case filed and what is the timeline pressure for FDA exclusivity and launch?

For ANDA-related patent cases:

• Filing date controls whether an automatic 30-month stay of FDA approval applies (if the dispute is timely filed in connection with a relevant Orange Book listing and certification).
• Subsequent events like claim construction orders, summary judgment, and trial schedules determine whether the case clears fast enough to govern FDA approval before launch windows.

Practical read: A 2023 filing places the case in the band where resolution timing often intersects with:

• the remaining term of the latest asserted patent in the Orange Book listing, and
• any exclusivity that would independently delay or condition FDA approval.

How does this case fit the Hatch-Waxman/ANDA framework?

Core structure (typical):

1. Nexus lists one or more patents in the Orange Book for a reference product.
2. Gland Pharma files an ANDA with a Paragraph IV or similar certification position.
3. Nexus sues within the Hatch-Waxman deadline.
4. The court litigates validity and infringement, and the outcome dictates whether Gland can obtain effective approval and launch.

Business impact mechanism:

• If Nexus wins infringement and the patents are upheld, FDA approval is blocked until expiration.
• If the patents are found invalid or not infringed, Gland can obtain approval and potentially launch promptly after FDA’s approval cycle completes.

What are the most likely litigation arguments each side uses?

Nexus Pharmaceuticals (plaintiff) typical arguments

• The ANDA product’s proposed composition falls within the asserted claim scope.
• The asserted patents are valid, including novelty and non-obviousness over the prior art.
• The ANDA filing constitutes infringement under the statutory “artificial infringement” framework.

Gland Pharma Limited (defendant) typical arguments

• Noninfringement: proposed ANDA formulation or method does not meet claim limitations.
• Invalidity: asserted claims are anticipated or obvious in view of earlier publications or patents.
• Procedural defenses: venue, standing, or claim construction disputes that narrow asserted coverage.
• Design-around feasibility: even if one claim is weak, other patents may govern launch.

What claim construction or case-management steps usually matter most in this posture?

In ANDA patent cases, the biggest practical levers tend to be:

• Claim construction orders that define how key terms are interpreted.
• Infringement contentions that lock in the comparison between ANDA product attributes and claim limitations.
• Expert testimony rulings that either constrain or support the invalidity/infringement analyses.

If the case reaches dispositive motions:

• Summary judgment on noninfringement often flows from a narrow claim construction.
• Summary judgment on invalidity often turns on a strong single-reference anticipation or a cohesive obviousness combination.

What is the likely effect on generic launch and revenue exposure?

This is the principal commercial question:

• If the asserted patents remain enforceable, Gland Pharma’s launch is deferred until expiration (or earlier settlement).
• If patents fall, the defendant’s ANDA can proceed to approval and launch as soon as the FDA grants approval and any stays lift.

Revenue exposure framework

• Nexus’s exposure is tied to how many months/years the generic entry is delayed.
• Gland’s exposure is tied to the value of market capture, time-to-launch costs, and potential damages if infringement is found after FDA approval.

Are there settlement, consent judgment, or licensing scenarios that typically end these cases?

ANDA patent cases frequently resolve by:

• Settlement agreements with stipulated launch dates.
• Covenants not to sue for certain product configurations.
• License terms (technology or branded-to-generic cross-rights).
• Dismissal with prejudice after payment and timing restrictions.

This docket posture is one where settlement is common, but the existence and terms of any settlement depend on filings that are case-specific.

What does the case mean for biosimilar risk, exclusivity stacking, or other product families?

Biosimilar risk is not the direct driver of an ANDA case; this is a small-molecule generic patent dispute. The more relevant concept is exclusivity stacking, where:

• multiple patents cover different elements (API, formulation, method),
• the last-to-expire patent blocks full market entry even if earlier patents fall.

How strong is the patent estate typically in an ANDA suit like this?

Strength is assessed by:

• claim breadth and how well prior art maps to core limitations,
• whether the asserted claims are well-supported by the specification,
• whether there are multiple independent claims covering different aspects of the product.

Even if a defendant knocks out one claim, the remaining claims often sustain the injunction or the practical launch barrier.

Which jurisdictions are affected by the case?

A federal district court judgment binds the parties and is enforceable through:

• injunctions and ongoing contempt risk,
• damages based on infringement periods.

However, patent enforceability and generic launch permissions are ultimately tied to US regulatory status and the patent listing that underpins the litigation.

What generic entry risks exist for Gland Pharma if Nexus prevails?

If Nexus prevails:

• FDA approval effectiveness can be blocked by the continuing existence of at least one valid infringed patent.
• Even after approval, the defendant can still face exposure if the court’s decision supports infringement and the “artificial infringement” framework is satisfied.

If Nexus partly prevails:

• Gland may still launch at risk or face a later blocking patent, depending on which claims are upheld.

What is the likely procedural end state?

The procedural endpoints in these cases typically include:

• Trial and final judgment
• Settlement and dismissal
• Consent judgment / entry of a stipulated injunction or non-infringement determination
• Dismissal on legal grounds (less common)

The end state determines whether Gland can launch immediately or only after specified dates.

---

Key Takeaways

• The case NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED (1:23-cv-02032) is an ANDA-style federal patent infringement dispute that turns on validity and infringement of one or more Orange Book-listed patents.
• Commercial impact is driven by whether any asserted patent survives. If yes, launch is delayed; if not, effective approval and entry can proceed.
• The biggest determinate steps in these matters are usually claim construction, expert-supported infringement mapping, and prior art/obviousness invalidity analytics.
• Case outcomes in this posture often resolve through settlement with launch-date terms, but the specific docket outcome must be verified from the case record.

---

FAQs

1) What happens to FDA approval timing in an ANDA patent case like 1:23-cv-02032?

2) Does a settlement in a Hatch-Waxman case usually grant an agreed launch date or a covenant not to sue?

3) If some asserted patents are found invalid, can Gland Pharma still launch and on what basis?

4) How do claim construction rulings typically determine infringement outcomes in ANDA litigation?

5) What types of patents (composition, formulation, method-of-use) most commonly block generic entry?

---

References (APA)

1. Docket information referenced by case caption and number: NEXUS PHARMACEUTICALS, INC. v. GLAND PHARMA LIMITED, No. 1:23-cv-02032 (D. Del. 2023).